Zobrazeno 1 - 10
of 137
pro vyhledávání: '"Richard S Geary"'
Autor:
Rosie Z Yu, Mark J Graham, Noah Post, Stan Riney, Thomas Zanardi, Shannon Hall, Jennifer Burkey, Colby S Shemesh, Thazha P Prakash, Punit P Seth, Eric E Swayze, Richard S Geary, Yanfeng Wang, Scott Henry
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 5, Iss C (2016)
Triantennary N-acetyl galactosamine (GalNAc3)-conjugated antisense oligonucleotides (ASOs) have greatly improved potency via receptor-mediated uptake. In the present study, the in vivo pharmacology of a 2′-O-(2-methoxyethyl)-modified ASO conjugated
Externí odkaz:
https://doaj.org/article/2b26807b841244429f7ffc38c01b9c47
Autor:
Rosie Z Yu, John S Grundy, Scott P Henry, Tae-Won Kim, Daniel A Norris, Jennifer Burkey, Yanfeng Wang, Andrew Vick, Richard S Geary
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 4, Iss C (2015)
Evaluation of species differences and systemic exposure multiples (or ratios) in toxicological animal species versus human is an ongoing exercise during the course of drug development. The systemic exposure ratios are best estimated by directly compa
Externí odkaz:
https://doaj.org/article/246f1041032e42dfa83f03452a855de3
Autor:
Michael Walsh, Claudette Bethune, Andrew Smyth, Jessica Tyrwhitt, Shiangtung W. Jung, Rosie Z. Yu, Yanfeng Wang, Richard S. Geary, Jeffrey Weitz, Sanjay Bhanot
Publikováno v:
Kidney International Reports, Vol 7, Iss 2, Pp 200-209 (2022)
Introduction: Patients with end-stage renal disease (ESRD) requiring hemodialysis (HD) have an increased risk of thrombotic events and bleeding. Antisense reduction of factor XI (FXI) with IONIS-FXIRx is a novel strategy that may safely reduce the ri
Externí odkaz:
https://doaj.org/article/9d5c672fdff6474baf02354f5b056319
Autor:
Nicholas J. Viney, Shuling Guo, Li‐Jung Tai, Brenda F. Baker, Mariam Aghajan, Shiangtung W. Jung, Rosie Z. Yu, Sheri Booten, Heather Murray, Todd Machemer, Sebastien Burel, Sue Murray, Gustavo Buchele, Sotirios Tsimikas, Eugene Schneider, Richard S. Geary, Merrill D. Benson, Brett P. Monia
Publikováno v:
ESC Heart Failure, Vol 8, Iss 1, Pp 652-661 (2021)
Abstract Aims Amyloidogenic transthyretin (ATTR) amyloidosis is a fatal disease characterized by progressive cardiomyopathy and/or polyneuropathy. AKCEA‐TTR‐LRx (ION‐682884) is a ligand‐conjugated antisense drug designed for receptor‐mediat
Externí odkaz:
https://doaj.org/article/3297462a8e6e4c1081fbb6040b37c72e
Autor:
Brenda F. Baker, Shuting Xia, Wesley Partridge, T. Jesse Kwoh, Sotirios Tsimikas, Sanjay Bhanot, Richard S. Geary
Publikováno v:
Nucleic Acid Therapeutics. 33:72-80
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54dc571f4f0996da54a23f710d864e2f
https://doi.org/10.1089/nat.2022.0044
https://doi.org/10.1089/nat.2022.0044
Autor:
Brenda F. Baker, Shuting Xia, Wesley Partridge, Richard S. Geary, Sanjay Bhanot, T. Jesse Kwoh
Publikováno v:
Nucleic Acid Therapeutics
The development process of antisense oligonucleotides (ASOs) as therapeutic agents in humans has advanced through the implementation of chemical compound modifications as well as increasingly sophisticated toxicological preclinical screening techniqu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3a15be03ddcace5a4a9c8c879eb0520
https://doi.org/10.1089/nat.2020.0917
https://doi.org/10.1089/nat.2020.0917
Autor:
Brenda F, Baker, Shuting, Xia, Wesley, Partridge, T Jesse, Kwoh, Sotirios, Tsimikas, Sanjay, Bhanot, Richard S, Geary
Publikováno v:
Nucleic acid therapeutics.
Receptor-mediated delivery of an antisense oligonucleotide (ASO) using the ligand-conjugated antisense technology is establishing a new benchmark for antisense therapeutics. The triantennary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1cac4ff6aa3549f8c0528a32a24803c8
https://pubmed.ncbi.nlm.nih.gov/36454263
https://pubmed.ncbi.nlm.nih.gov/36454263
Autor:
Sanjay Bhanot, Eleonora Marostica, Maximilian Lobmeyer, Nelleke Snelder, Erin E. Morgan, Anthonie W. A. Lensing, Richard S. Geary, Markus Jensen, Shiangtung W. Jung, Yanfeng Wang, Rosie Z. Yu, Stefan Willmann, Claudette Bethune, Alexander Solms
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 8, Pp 890-901 (2021)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology
IONIS‐FXIRX (BAY2306001) is an antisense oligonucleotide that inhibits the synthesis of coagulation factor XI (FXI) and has been investigated in healthy volunteers and patients with end‐stage renal disease (ESRD). FXI‐LICA (BAY2976217) shares t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c833bb12274e461ae57144f261c44b4
https://doaj.org/article/a0f07a9e368749df85e58f6529f928d9
https://doaj.org/article/a0f07a9e368749df85e58f6529f928d9
Autor:
Shiangtung W. Jung, Li Jung Tai, Márcia Waddington-Cruz, William J. Litchy, Sotirios Tsimikas, Peter J. Dyck, Cecilia Monteiro, Gustavo Buchele, Julian D. Gillmore, Michela Brambatti, John L. Berk, Eugene Schneider, Yukio Ando, Teresa Coelho, Morie A. Gertz, Merrill D. Benson, Nicholas J. Viney, Louis O'Dea, Richard S. Geary, Brett P. Monia, Sami Khella, Laura Obici
Publikováno v:
Neurology and therapy, vol 10, iss 1
Neurology and Therapy
Neurology and Therapy
Introduction AKCEA-TTR-LRx is a ligand-conjugated antisense (LICA) drug in development for the treatment of hereditary transthyretin amyloidosis (hATTR), a fatal disease caused by mutations in the transthyretin (TTR) gene. AKCEA-TTR-LRx shares the sa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cae92472f0364a8018070ff0215ebd0d
https://doi.org/10.1007/s40120-021-00235-6
https://doi.org/10.1007/s40120-021-00235-6
Autor:
Elif A, Oral, Abhimanyu, Garg, Joseph, Tami, Eric A, Huang, Louis St L, O'Dea, Hartmut, Schmidt, Anatoly, Tiulpakov, Ann, Mertens, Veronica J, Alexander, Lynnetta, Watts, Eunju, Hurh, Joseph L, Witztum, Richard S, Geary, Sotirios, Tsimikas
Publikováno v:
Journal of clinical lipidology. 16(6)
Volanesorsen, an antisense oligonucleotide, is designed to inhibit hepatic apolipoprotein C-III synthesis and reduce plasma apolipoprotein C-III and triglyceride concentrations.The present study assessed efficacy and safety of volanesorsen in patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d74f88998c3968a3567577a36b040b98
https://pubmed.ncbi.nlm.nih.gov/36402670
https://pubmed.ncbi.nlm.nih.gov/36402670